Related Experiment Videos
BRCA1 IVS16+6T-->C is a deleterious mutation that creates an aberrant transcript by activating a cryptic splice donor
1Myriad Genetic Laboratories, Salt Lake City, Utah 84108, USA. tscholl@myriad.com
American Journal of Medical Genetics
|July 16, 1999
Summary
The BRCA1 IVS16+6T-->C mutation creates a faulty RNA transcript, leading to a non-functional, truncated BRCA1 protein. This finding identifies a deleterious mutation impacting breast cancer risk.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- The BRCA1 gene is crucial for DNA repair and tumor suppression.
- Mutations in BRCA1 significantly increase the risk of breast and ovarian cancers.
- Understanding the functional impact of specific BRCA1 variants is essential for genetic counseling and risk assessment.
Observation:
- A specific intronic variant, BRCA1 IVS16+6T-->C, was identified in a breast cancer patient.
- Analysis of peripheral blood mononuclear cells revealed aberrant RNA splicing associated with this variant.
- The aberrant transcript incorporated intronic sequences and contained premature stop codons.
Findings:
- The BRCA1 IVS16+6T-->C mutation activates a cryptic splice site, leading to the production of a truncated, non-functional protein.
- This aberrant splicing event results in the loss of a heterozygous base within codon 871.
- Sequence analysis confirmed that productive mRNA and aberrantly spliced RNA originate from separate alleles.
Implications:
- The BRCA1 IVS16+6T-->C variant is characterized as a deleterious mutation.
- This finding has implications for accurate genetic testing and interpretation of BRCA1 variants in breast cancer patients.
- Identifying the precise mechanism of splicing defects aids in understanding genotype-phenotype correlations in hereditary cancers.